A limitation in the visual rating system itself is that it does not distinguish the specific areas of the neocortex involved, and it does not explicitly demarcate moderate to advanced tau burden as a discrete category, as recommended in the revised AD biomarker framework.33 This evidence concerns the gene MAPT and Alzheimer disease.